Much more at this link than is copy and pasted below.
https://wattsupwiththat.com/2020/07/05/hypothesis-restrictions-on-hydroxychloroquine-contribute-to-the-covid-19-cases-surge/Hypothesis: Restrictions on Hydroxychloroquine Contribute to the COVID-19 Cases Surge
Guest Blogger / July 5, 2020
guest post by Leo Goldstein
[cr note: This is an interesting hypothesis from Leo Goldstein. I’ll add some observations]
We have a sharp surge in the new COVID-19 cases. The main [or just one factor out of several, a contributor ~cr] cause is likely to be the drop in the use of Hydroxychloroquine based treatment, following the FDA Memorandum of June 15. The FDA Memorandum accompanied the revocation of the Emergency Use Authorization for Hydroxychloroquine and Chloroquine from the National Strategic Stockpile. The FDA Memorandum vilified the drug, falsely alleging that it is not safe and “unlikely to be effective” against COVID-19 – when thousands of doctors have treated hundreds of thousands of patients with it . The National Institutes of Health’s NIH COVID-19 Panel updated its Guidelines to match on the FDA’s opinion the next day.
Although Hydroxychloroquine remains an approved drug and doctors can still prescribe it off-label, the FDA’s and NIH’s opinions have significant influence. State governments and medical boards adhere to the FDA opinion, in their subsequent recommendations. Even when HCQ is not banned outright, such opinion creates a chilling effect on pharmacies, doctors, hospitals, and, especially insurance companies.
From the declaration by Jeremy Snavely, 6/22:
Multiple members of AAPS have communicated to AAPS their inability to prescribe hydroxychloroquine (HCQ) for a full regimen to treat or prevent COVID-19, including but not limited to physicians in Western Michigan, Georgia, New Jersey, Arizona, and Texas.
…
Numerous physician members of AAPS, including this “Dr. John
Doe,” reasonably fear retaliation against them by state medical boards based on
Defendants’ irrational restrictions on HCQ along with the incorporation of the
directive made to state medical boards by the Federation of State Medical Boards.
(ASSOCIATION OF AMERICAN PHYSICIANS & SURGEONS v FDA et al, 1:20-cv-00493, FEDERAL COURT FOR THE WESTERN DISTRICT OF MICHIGAN)
HCQ Benefits
It is important to note that early antiviral treatment of patients with COVID-19 symptoms, using HCQ + AZ (+Zn), benefits not only the patient, but the public in general. Such treatment quickly reduces the viral load in the patient and the chances of the further transmission. [While this may be the case, generally evidence at this time only exists for improved outcomes for patients~cr]
Fig. 1. US daily new confirmed COVID-19 cases per day, 7-day rolling average (*)
